MEI Pharma (United States)

Recent papers from MEI Pharma (United States)

1. Simulating an intravenous-to-oral cefotaxime-to-cefditoren/cefuroxime switch: an in vitro pharmacodynamic approach against selected Streptococcus pneumoniae strains with defined susceptibility profilesFrontiers in Pharmacology · 2026
2. Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3The Oncologist · 2026
3. Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid TumorsThe Oncologist · 2026
4. Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitorsSTAR Protocols · 2026
5. OP-NEU-101: A phase 1/2 open-label, dose finding and expansion study to investigate the safety and effectiveness and determine the optimal dose of N17350 administered intratumorally in participants with advanced solid tumors.Journal of Clinical Oncology · 2026
6. Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistanceBioconjugation Insights · 2026
7. Abstract 310: Translational development of NEU-002: Engineered therapeutic elastases demonstrate systemic anti-tumor activity via intraperitoneal and intravenous administration.Cancer Research · 2026
8. Advances in microbial sulfoquinovose catabolismFrontiers in Microbiology · 2026
9. Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cellsCell Reports Medicine · 2025
10. The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaBlood Neoplasia · 2025
11. Antibiotic susceptibility of pathogens isolated in respiratory tract samples of recently hospitalized patientsMicrobiology Spectrum · 2025
12. A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerInvestigational New Drugs · 2024
13. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesBlood Advances · 2024
14. Phase I–II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology · 2024
15. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyHemaSphere · 2024
16. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomasBritish Journal of Haematology · 2024
17. Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive CancersJournal of Immunotherapy · 2021
18. Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interactionChemical Communications · 2020
19. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma ModelsTargeted Oncology · 2019
20. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapyBritish Journal of Haematology · 2019